NCT05054543 is a Phase 3 clinical trial of Uproleselan in Relapsed/Refractory AML, sponsored by Apollomics Inc..

Who is sponsoring NCT05054543?

NCT05054543 is sponsored by Apollomics Inc..

What drugs are being tested in NCT05054543?

Interventions in NCT05054543: Uproleselan, Placebo.

What condition does NCT05054543 study?

NCT05054543 studies Relapsed/Refractory AML.

Is NCT05054543 still recruiting?

NCT05054543 is currently terminated. Last updated 27 June 2025.

Last reviewed 2025-06-27 · How we verify

NCT05054543

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Terminated Phase 3 Last updated 27 June 2025

What this trial tests

Phase 3 trial testing Uproleselan in Relapsed/Refractory AML in 140 participants. Terminated before completion.

Timeline

17 November 2021

Primary endpoint
22 August 2024

22 August 2024

Quick facts

Lead sponsor	Apollomics Inc.
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	140
Start date	17 November 2021
Primary completion	22 August 2024
Estimated completion	22 August 2024
Sites	2 locations across China

Drugs / interventions tested

Uproleselan — full drug profile →
Placebo

Conditions studied

Relapsed/Refractory AML — all drugs for Relapsed/Refractory AML →

Sponsor

Apollomics Inc. — full company profile →

Who can join

Adults 18 to 75, any sex, with Relapsed/Refractory AML. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This bridging study will evaluate the efficacy of uproleselan, a specific E-selectin antagonist, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Recent advances in targeted therapies in acute myeloid leukemia.
Bhansali RS, Pratz KW, Lai C. · · 2023 · cited 151× · PMID 36966300 · DOI 10.1186/s13045-023-01424-6
Glycomimetics for the inhibition and modulation of lectins.
Leusmann S, Ménová P, Shanin E, Titz A, et al · · 2023 · cited 73× · PMID 37232696 · DOI 10.1039/d2cs00954d
P- and E- selectin in venous thrombosis and non-venous pathologies.
Purdy M, Obi A, Myers D, Wakefield T. · · 2022 · cited 60× · PMID 35243742 · DOI 10.1111/jth.15689
Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives.
Leotta S, Condorelli A, Sciortino R, Milone GA, et al · · 2022 · cited 36× · PMID 35011994 · DOI 10.3390/jcm11010253
Remodeling of the bone marrow microenvironment during acute myeloid leukemia progression.
Urs AP, Goda C, Kulkarni R. · · 2024 · cited 11× · PMID 39118939 · DOI 10.21037/atm-23-1824
Targeting hematologic malignancies by inhibiting E-selectin: A sweet spot for AML therapy?
Uy GL, DeAngelo DJ, Lozier JN, Fisher DM, et al · · 2024 · cited 7× · PMID 38493006 · DOI 10.1016/j.blre.2024.101184

Verify or expand the search:

Other trials of Uproleselan

Trials testing the same drug.

NCT05146739 — Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Mye · Phase 1 · active not recruiting
NCT05569512 — Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML · Phase 1 · terminated
NCT05057221 — Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia · Phase 1, PHASE2 · terminated
NCT04964505 — Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia · Phase 1 · terminated
NCT04848974 — Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leuk · Phase 1, PHASE2 · completed

Other Apollomics Inc. trials

Trials by the same sponsor.

NCT05055518 — APL-102 Capsule in Patients With Advanced Solid Tumors · Phase 1 · suspended
NCT04839341 — Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients · Phase 1 · completed
NCT03175224 — APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05054543 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Apollomics Inc.
Last refreshed: 27 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05054543.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing